185 related articles for article (PubMed ID: 16283715)
1. Oligonucleotide structure influences the interactions between cationic polymers and oligonucleotides.
Sundaram S; Viriyayuthakorn S; Roth CM
Biomacromolecules; 2005; 6(6):2961-8. PubMed ID: 16283715
[TBL] [Abstract][Full Text] [Related]
2. Characterization of interaction between cationic lipid-oligonucleotide complexes and cellular membrane lipids using confocal imaging and fluorescence correlation spectroscopy.
Gordon SP; Berezhna S; Scherfeld D; Kahya N; Schwille P
Biophys J; 2005 Jan; 88(1):305-16. PubMed ID: 15516528
[TBL] [Abstract][Full Text] [Related]
3. Controlled release of NFkappaB decoy oligonucleotides from biodegradable polymer microparticles.
Zhu X; Lu L; Currier BL; Windebank AJ; Yaszemski MJ
Biomaterials; 2002 Jul; 23(13):2683-92. PubMed ID: 12059017
[TBL] [Abstract][Full Text] [Related]
4. Controlled delivery of antisense oligodeoxynucleotide from cationically modified phosphorylcholine polymer films.
Zhang Z; Cao X; Zhao X; Withers SB; Holt CM; Lewis AL; Lu JR
Biomacromolecules; 2006 Mar; 7(3):784-91. PubMed ID: 16529415
[TBL] [Abstract][Full Text] [Related]
5. A novel anionic dendrimer for improved cellular delivery of antisense oligonucleotides.
Hussain M; Shchepinov M; Sohail M; Benter IF; Hollins AJ; Southern EM; Akhtar S
J Control Release; 2004 Sep; 99(1):139-55. PubMed ID: 15342187
[TBL] [Abstract][Full Text] [Related]
6. Site-specific administration of antisense oligonucleotides using biodegradable polymer microspheres provides sustained delivery and improved subcellular biodistribution in the neostriatum of the rat brain.
Khan A; Sommer W; Fuxe K; Akhtar S
J Drug Target; 2000; 8(5):319-34. PubMed ID: 11328659
[TBL] [Abstract][Full Text] [Related]
7. Controlled delivery of anti-sense oligodeoxynucleotide from multilayered biocompatible phosphorylcholine polymer films.
Zhang Z; Cao X; Zhao X; Holt CM; Lewis AL; Lu JR
J Control Release; 2008 Aug; 130(1):69-76. PubMed ID: 18562037
[TBL] [Abstract][Full Text] [Related]
8. Interference of poly(ethylene glycol)-lipid analogues with cationic-lipid-mediated delivery of oligonucleotides; role of lipid exchangeability and non-lamellar transitions.
Shi F; Wasungu L; Nomden A; Stuart MC; Polushkin E; Engberts JB; Hoekstra D
Biochem J; 2002 Aug; 366(Pt 1):333-41. PubMed ID: 12030844
[TBL] [Abstract][Full Text] [Related]
9. Cationic lipids reduce time and dose of c-myc antisense oligodeoxynucleotides required to specifically inhibit Burkitt's lymphoma cell growth.
Williams SA; Chang L; Buzby JS; Suen Y; Cairo MS
Leukemia; 1996 Dec; 10(12):1980-9. PubMed ID: 8946941
[TBL] [Abstract][Full Text] [Related]
10. Development of a sustained-release biodegradable polymer delivery system for site-specific delivery of oligonucleotides: characterization of P(LA-GA) copolymer microspheres in vitro.
Lewis KJ; Irwin WJ; Akhtar S
J Drug Target; 1998; 5(4):291-302. PubMed ID: 9713978
[TBL] [Abstract][Full Text] [Related]
11. Studying the intracellular dissociation of polymer-oligonucleotide complexes by dual color fluorescence fluctuation spectroscopy and confocal imaging.
Lucas B; Remaut K; Sanders NN; Braeckmans K; De Smedt SC; Demeester J
Biochemistry; 2005 Jul; 44(29):9905-12. PubMed ID: 16026163
[TBL] [Abstract][Full Text] [Related]
12. VP22 light controlled delivery of oligonucleotides to ocular cells in vitro and in vivo.
Normand N; Valamanesh F; Savoldelli M; Mascarelli F; BenEzra D; Courtois Y; Behar-Cohen F
Mol Vis; 2005 Mar; 11():184-91. PubMed ID: 15761390
[TBL] [Abstract][Full Text] [Related]
13. Physicochemical and disposition characteristics of antisense oligonucleotides complexed with glycosylated poly(L-lysine).
Mahato RI; Takemura S; Akamatsu K; Nishikawa M; Takakura Y; Hashida M
Biochem Pharmacol; 1997 Mar; 53(6):887-95. PubMed ID: 9113108
[TBL] [Abstract][Full Text] [Related]
14. Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells.
Zelphati O; Uyechi LS; Barron LG; Szoka FC
Biochim Biophys Acta; 1998 Feb; 1390(2):119-33. PubMed ID: 9507083
[TBL] [Abstract][Full Text] [Related]
15. Efficient delivery of intact phosphodiester oligonucleotides by poly-beta-amino esters.
Remaut K; Symens N; Lucas B; Demeester J; De Smedt SC
J Control Release; 2010 May; 144(1):65-74. PubMed ID: 20114066
[TBL] [Abstract][Full Text] [Related]
16. A lipid carrier with a membrane active component and a small complex size are required for efficient cellular delivery of anti-sense phosphorothioate oligonucleotides.
Jääskeläinen I; Peltola S; Honkakoski P; Mönkkönen J; Urtti A
Eur J Pharm Sci; 2000 May; 10(3):187-93. PubMed ID: 10767596
[TBL] [Abstract][Full Text] [Related]
17. Mixed polymer micelles of amphiphilic and cationic copolymers for delivery of antisense oligonucleotides.
Vinogradov SV; Batrakova EV; Li S; Kabanov AV
J Drug Target; 2004; 12(8):517-26. PubMed ID: 15621677
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition.
Mok H; Park JW; Park TG
Bioconjug Chem; 2007; 18(5):1483-9. PubMed ID: 17602578
[TBL] [Abstract][Full Text] [Related]
19. Synthetic hydrogels as carriers in antisense therapy: preliminary evaluation of an oligodeoxynucleotide covalent conjugate with a copolymer of 1-vinyl-2-pyrrolidinone and 2-hydroxyethyl methacrylate.
Lou X; Garrett KL; Rakoczy PE; Chirila TV
J Biomater Appl; 2001 Apr; 15(4):307-20. PubMed ID: 11336385
[TBL] [Abstract][Full Text] [Related]
20. Delivery of antisense oligonucleotide to the cornea by iontophoresis.
Berdugo M; Valamanesh F; Andrieu C; Klein C; Benezra D; Courtois Y; Behar-Cohen F
Antisense Nucleic Acid Drug Dev; 2003 Apr; 13(2):107-14. PubMed ID: 12804037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
